Key Takeaways:
Powered by lumidawealth.com
• Insurers received $50 billion in extra payments for unverified diagnoses (2019-2021)
• Home visits by insurance nurses generated $15 billion in additional payments
• Veterans’ enrollment in Medicare Advantage plans led to significant insurer profits
• High dropout rates among seriously ill patients suggest systematic care denial
What Happened?
The Wall Street Journal’s investigation revealed systematic practices by major health insurers, particularly UnitedHealth Group, to maximize payments from the $450 billion Medicare Advantage program. The investigation, based on billions of Medicare service records, showed insurers adding diagnoses without corresponding treatments, conducting questionable home visits for additional diagnoses, and targeting veterans who primarily used VA healthcare. UnitedHealth’s doctors were found to be using diagnosis checklists that resulted in patients appearing 55% sicker on paper after switching from traditional Medicare.
Why It Matters?
This investigation exposes significant flaws in the Medicare Advantage system that impact both taxpayers and patients. The findings suggest systematic exploitation of payment rules, potentially adding billions to healthcare costs while not necessarily improving patient care. The practice of adding unverified diagnoses and targeting healthier veterans raises serious questions about the program’s efficiency and oversight. The high dropout rates among seriously ill patients particularly highlight potential issues with care access for those who need it most.
What’s Next?
The revelations are likely to trigger increased regulatory scrutiny and potential reforms in the Medicare Advantage program. The HHS inspector general’s recommendation to end payments for diagnoses from home visits alone signals possible policy changes. Watch for: Congressional investigations, regulatory reforms in diagnosis verification requirements, changes in payment structures, and potential restrictions on veteran-focused marketing. Investors should monitor how these developments might impact major insurers’ revenue streams and business models, particularly those heavily invested in Medicare Advantage programs.
